Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chin-Shern Lau

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Vaccines|January 21, 2023
Considerations in Understanding Vaccine EffectivenessChin Shern Lau, Tar Choon Aw
Antibodies (Basel, Switzerland)|December 23, 2021
Disease Prevalence Matters: Challenge for SARS-CoV-2 TestingChin-Shern Lau, Tar-Choon Aw
Diagnostics (Basel, Switzerland)|May 28, 2022
SARS-CoV-2 Antigen Testing Intervals: Twice or Thrice a Week?Chin Shern Lau, Tar-Choon Aw
Vaccines|January 24, 2025
Reflections on COVID-19: A Literature Review of SARS-CoV-2 TestingChin Shern Lau, Helen M L Oh, Tar Choon Aw
The Journal of Applied Laboratory Medicine|October 17, 2020
Faster HbA1c Turnaround Times Using a Dedicated Analyzer Based on Turbidimetric Inhibition Immunoassay TechnologyChin Shern Lau, Melva Lim, See Ping Hoo, et al.
Vaccines|February 26, 2022
Evaluation and Validation of the Roche Elecsys SARS-CoV-2 Antigen Electro-Chemiluminescent Immunoassay in a Southeast Asian RegionChin Shern Lau, Soon Kieng Phua, See Ping Hoo, et al.
Diagnostics (Basel, Switzerland)|October 16, 2025
99th-Percentile Upper Reference Limit for the New Snibe High-Sensitivity Troponin I Assay in a Southeast Asian PopulationYun Zhang, Chin Shern Lau, Ke Yang, et al.
Vaccines|February 26, 2022
SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in SingaporeChin Shern Lau, Soon Kieng Phua, Ya Li Liang, et al.
Vaccines|November 27, 2021
Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 VaccineChin-Shern Lau, Soon Kieng Phua, Ya-Li Liang, et al.
Vaccines|October 27, 2022
210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA VaccineChin Shern Lau, May Lin Helen Oh, Soon Kieng Phua, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Vaccines|January 21, 2023
Considerations in Understanding Vaccine EffectivenessChin Shern Lau, Tar Choon Aw
Antibodies (Basel, Switzerland)|December 23, 2021
Disease Prevalence Matters: Challenge for SARS-CoV-2 TestingChin-Shern Lau, Tar-Choon Aw
Diagnostics (Basel, Switzerland)|May 28, 2022
SARS-CoV-2 Antigen Testing Intervals: Twice or Thrice a Week?Chin Shern Lau, Tar-Choon Aw
Vaccines|January 24, 2025
Reflections on COVID-19: A Literature Review of SARS-CoV-2 TestingChin Shern Lau, Helen M L Oh, Tar Choon Aw
The Journal of Applied Laboratory Medicine|October 17, 2020
Faster HbA1c Turnaround Times Using a Dedicated Analyzer Based on Turbidimetric Inhibition Immunoassay TechnologyChin Shern Lau, Melva Lim, See Ping Hoo, et al.
Vaccines|February 26, 2022
Evaluation and Validation of the Roche Elecsys SARS-CoV-2 Antigen Electro-Chemiluminescent Immunoassay in a Southeast Asian RegionChin Shern Lau, Soon Kieng Phua, See Ping Hoo, et al.
Diagnostics (Basel, Switzerland)|October 16, 2025
99th-Percentile Upper Reference Limit for the New Snibe High-Sensitivity Troponin I Assay in a Southeast Asian PopulationYun Zhang, Chin Shern Lau, Ke Yang, et al.
Vaccines|February 26, 2022
SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in SingaporeChin Shern Lau, Soon Kieng Phua, Ya Li Liang, et al.
Vaccines|November 27, 2021
Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 VaccineChin-Shern Lau, Soon Kieng Phua, Ya-Li Liang, et al.
Vaccines|October 27, 2022
210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA VaccineChin Shern Lau, May Lin Helen Oh, Soon Kieng Phua, et al.
Pageof 2